Typical Bridging Agents with Warfarin
The typical bridging agents used when transitioning patients off warfarin are low molecular weight heparin (LMWH) or unfractionated heparin (UFH), with LMWH being preferred for outpatient management. 1, 2
Primary Bridging Agents
Low Molecular Weight Heparin (LMWH) is the most commonly used bridging agent, typically administered as:
- Therapeutic dosing: Started when INR falls below therapeutic range (usually <2.0), approximately 36-48 hours after the last warfarin dose (3 days preoperatively) 1, 3
- Timing: Last preprocedural dose given 24 hours before surgery at half the total daily dose 1, 3
- Common formulations: Enoxaparin and dalteparin are the most frequently used 4, 5, 6
Unfractionated Heparin (UFH) is the alternative bridging agent, particularly indicated for:
- Patients with severe renal impairment (creatinine clearance <30 mL/min) 1, 5
- Situations requiring rapid reversal capability
- Timing: Stopped 4-6 hours before the procedure 1
- Disadvantage: Requires hospitalization and frequent monitoring 3
Critical Context: When Bridging Is Actually Indicated
Most patients do NOT need bridging. The 2016 BRIDGE trial fundamentally changed practice by demonstrating that bridging increases bleeding risk without reducing thromboembolism 2. Current guidelines recommend bridging only for very high-risk patients:
High-Risk Patients Who Should Receive Bridging:
- Mechanical heart valves (especially mitral position) 2, 7
- CHADS₂ score ≥4-6 (or recent stroke/TIA within 3 months) 2, 7
- Rheumatic heart disease 1, 2
- Antiphospholipid syndrome with recurrent thrombosis 3, 6
- Recent VTE within 3 months 8
Patients Who Should NOT Receive Bridging:
- Most atrial fibrillation patients with lower CHADS₂ scores (<4) 2
- Patients on direct oral anticoagulants (DOACs) - bridging is generally not necessary due to their short half-lives 1, 2
Postprocedural Bridging Protocol
After the procedure, when bridging is used:
- Low bleeding risk procedures: Resume LMWH at therapeutic dose 24 hours post-procedure 1
- High bleeding risk procedures: Resume LMWH at prophylactic doses for 24-72 hours, then increase to therapeutic doses once hemostasis is secured (typically 48-72 hours) 1, 3
- Continue bridging until INR returns to therapeutic range (≥2.0) on warfarin 1, 3
Important Caveats
Bridging significantly increases bleeding risk (3.2% vs 1.3% major bleeding) without reducing thromboembolism in most patients 2. The evidence consistently shows a 2-3 fold increase in major bleeding with bridging therapy 2, 9, 10.
Warfarin can be restarted the evening of or morning after the procedure at the usual maintenance dose, with bridging continued until therapeutic INR is achieved 1, 3, 11.